Ciba's Revasc (desirudin) equivalent to heparin for acute MI -- TIMI 9B study.
CIBA's REVASC EQUIVALENT TO HEPARIN FOR PREVENTION OF DEATH AND MI in patients with acute MI following thrombolysis, according to results from Thrombolysis in Myocardial Infarction (TIMI) 9B trial with the recombinant hirudin product. The results were reported Nov. 12 at a George Washington University Medical Center-sponsored Workshop on Thrombolysis and International Therapy in Acute Myocardial Infarction preceding the annual American Heart Association meeting in Anaheim.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth